New Customized Fluid Transfer Service Simplifies the Biopharmaceutical Manufacturing Process
Today’s manufacturers searching to simplify their supply chains and sharpen their production capabilities can benefit from a new fluid transfer service specifically for aseptic biopharmaceutical production.
The Thermo Scientific Customized Fluid Transfer Service provides pre-sterilized and ready-to-use consumables tailored for a customer’s facility needs, freeing up the manufacturer’s time to focus on critical operations while optimizing cleanroom usage.
Within a current good manufacturing practice (cGMP) facility, the need for a cost-effective aseptic approach to fluid transfer can place a sizable strain upon resources. Manufacturers must implement intelligent strategies to manage the complex supply chains of containers, tubing, filters and connectors — all of which need to be sterilized. This approach creates numerous operations, quality and regulatory challenges. Partnering with a single, trusted supplier to develop a customized turnkey fluid transfer solution can significantly simplify supply chain and inventory management.
“Our systems are custom built to each manufacturing facility’s needs and eliminate any on-site assembly, which not only saves time and resources, but reduces the potential for loss of sterility through human error,” said Myriam Jordan, business director, vaccines and biologics, Thermo Fisher Scientific. “By partnering with us, users can obtain a fluid transfer system that has undergone rigorous testing to meet mutually agreed upon standards, while streamlining supply chain management.”
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...